Loading
Life sciences · Journal article
Discover Oncology · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Protein S-palmitoylation is a reversible lipid post-translational modification (PTM) that controls protein localization, stability, trafficking, and signaling. In cancer, this modification does not act as a simple oncogenic switch. Its effects depend on the substrate, the palmitoyltransferase or depalmitoylase involved, the tumor lineage, and the immune context. In some settings, palmitoylation sustains oncogenic signaling, metabolic rewiring, stemness, ferroptosis resistance, and immune escape. In others, it restrains tumor growth or improves therapeutic sensitivity by limiting key signaling pathways or preserving antigen presentation. This context dependence is especially important in the tumor microenvironment (TME), where palmitoylation can shape T cell exhaustion, natural killer (NK) cell cytotoxicity, macrophage polarization, myeloid-derived suppressor cell (MDSC) expansion, and immune checkpoint protein stability. This mini-review summarizes the enzymatic regulation and detection of protein S-palmitoylation, highlights its roles in tumor progression and immune regulation, and discusses how palmitoylation-targeted strategies may improve cancer therapy. Rather than viewing global inhibition as a universal solution, we emphasize the need to define substrate-specific and cell type-specific palmitoylation programs. Such precision will be critical for translating this dynamic PTM into rational combinations with chemotherapy, radiotherapy, targeted therapy, and immune checkpoint inhibitors (ICIs).